Clinical Development of CT327, a novel treatment for childhood Atopic Dermatitis

A small biotech company is testing a new topical cream for childhood eczema that targets the itch itself, not just the rash. This matters because severe childhood eczema—atopic dermatitis—affects roughly one in five children in the UK, and existing treatments have significant drawbacks. Steroid creams can thin the skin with long-term use, while newer immune-suppressing drugs carry safety concerns. The itch is often the most debilitating symptom, disrupting sleep and daily life, yet no current topical treatment directly addresses it. CT327 works through a novel mechanism of action, and its Low Systemic Exposure design keeps the drug largely in the skin, reducing the risk of side effects seen in five earlier clinical studies. If this Phase 2b trial succeeds, CT327 could become the first long-term topical treatment for childhood eczema that safely controls all symptoms—including itch—without the safety concerns of steroids or systemic drugs. For families, that could mean fewer sleepless nights and less reliance on treatments that require careful monitoring. For the NHS, it could reduce the burden of specialist referrals and emergency visits for severe flare-ups.